XPAR
EL
Market cap74bUSD
Sep 17, Last price
141.45EUR
1D
-2.52%
1Q
-18.50%
Jan 2017
31.77%
Name
EssilorLuxottica SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
EssilorLuxottica S.A., established in Paris, France, in 1849, is a global enterprise dedicated to the design, production, and distribution of a wide range of ophthalmic products, including corrective lenses, eyewear frames, and sunglasses. The company extends its reach across North America, Europe, Latin America, Asia, Oceania, and Africa. Its operations are structured into five key divisions: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale division handles the manufacturing and large-scale distribution of luxury and performance eyewear. Conversely, the Retail segment is responsible for the direct sale of these premium and athletic vision products to consumers. The Lenses and Optical Instruments segment offers an extensive portfolio of advanced lens technologies, including Varilux progressive lenses, Crizal anti-reflective and anti-smudge coatings, Transitions photochromic lenses (featuring the latest Signature Gen 8), Eyezen lenses optimized for digital screen users, and Xperio polarized sun lenses, alongside corrective lens brands under license such as Nikon and Kodak. This segment also provides essential equipment like lens edging and mounting tools for opticians and laboratories, as well as optometry instruments for eye care professionals, educational bodies, military, and other organizations, while also developing digital platforms for online optical sales. The Equipment division supplies sophisticated digital surfacing and lens coating machinery to prescription laboratories, integrated optical networks, and lens manufacturers worldwide. Finally, the Sunglasses and Readers segment focuses on non-prescription eyewear, offering a diverse collection of sunglasses and reading glasses through various owned brands like Foster Grant, Magnivision, and Ryders Eyewear; licensed brands including Reebok, Steve Madden, Marvel, and Disney; and regional labels such as Bolon and Mujosh. EssilorLuxottica maintains a substantial operational network, encompassing 490 prescription laboratories and edging-mounting facilities. The company, initially known as Essilor International Société Anonyme, adopted its current name in October 2018.
Related entities
Subsidiaries (96)
ESSILOR SOUTH AFRICA
ESSILOR TECHNOLOGY + SERVICES CENTER SWITZERLAND AG
ESSILOR TIJUANA OPTICA S DE RL DE CV
ESSILORLUXOTTICA USA INC.
EYEBIZ LABORATORY (THAILAND) CO.,LTD.
FABRIS LANE LTD.
FGX Canada Corp.
FGX EUROPE LIMITED
FGX INTERNATIONAL INC.
FGX Latin America S. de R.L. de C.V.
Future Eyewear Group Sweden AB
GKB OPTIC TECHNOLOGIES PRIVATE LIMITED
GRANDVISION CZ S.R.O.
GRANDVISION FRANCE
GRANDVISION HUNGARY KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG
GrandVision Supply Chain B.V.
HOLLAND OPTICAL COMPANY B.V.
ILT LATIN AMERICA PTE. LTD.
Instru Optiikka Oy
INTEGRATED LENS TECHNOLOGY PTE. LTD.
Key people
David Wielemans
Co-Chief Financial Officer · since 2020
Veronique Gillet
Senior Vice President, Investor Relations and Financial Communications · since 2016
Eric Leonard
Chief Integration Officer · since 2018
Jayanth Bhuvaraghan
Chief Mission Officer, Member of the Management Committee · since 2013
Non-Independent Director · since 2018
Paul du Saillant
Chief Executive Officer of Essilor, Non-independent director · since 2020
Juliette Favre
Director - Representative of Valoptec Association · since 2019
Annette Messemer
Independent Director · since 2016
Delphine Zablocki
Director - Representing Employees · since 2017
Lucia Morselli
Independent Director · since 2018
Independent Director · since 2018
Independent Director · since 2017
IPO date
Jan 01, 1975
Employees
191,144
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
147 RUE DE PARIS
CHARENTON-LE-PONT, 94 94220
FR
CHARENTON-LE-PONT, 94 94220
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||